This article is more than 5 years old. Information may no longer be current.

VIDEO: Enfortumab vedotin demonstrates encouraging activity in metastatic urothelial carcinoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Steven E. Benner, MD, MHS, senior vice president and therapeutic area head of oncology at Astellas Pharma, provided HemOnc Today with an overview of key data the company presented at ASCO Annual Meeting.

A phase 1 study showed the potential efficacy of the antibody-drug conjugate enfortumab vedotin (ASG-22ME; Seattle Genetics, Astellas) for the treatment of metastatic urothelial carcinoma.

Researchers also presented updated quality-of-life data from the phase 3 PROSPER trial, which evaluated the addition of enzalutamide (Xtandi; Astellas, Pfizer) to androgen deprivation therapy for patients with nonmetastatic castration-resistant prostate cancer.

In this video, Benner also provided an overview of regulatory developments related to Astellas agents and explained how the company is increasing its emphasis on immuno-oncology.